Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study
Abstract Real‐world data (RWD) reflecting patient treatment in routine clinical practice can be used to develop external control groups for single‐arm trials. External controls can provide valuable benchmark results on potential comparator drug effectiveness, particularly in rare indications when ra...
Saved in:
Main Authors: | Dina Oksen (Author), Patricia Prince (Author), Emmanuelle Boutmy (Author), Elizabeth M. Garry (Author), Barbara Ellers‐Lenz (Author), Adina Estrin (Author), Andreas Johne (Author), Patrice Verpillat (Author), Nicolle M. Gatto (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany
by: Klaus F. Bühler, et al.
Published: (2021) -
Pricing of orphan drugs in oncology and rare diseases
by: Mark Nuijten, et al.
Published: (2020) -
Measurement error and bias in real-world oncology endpoints when constructing external control arms
by: Benjamin Ackerman, et al.
Published: (2024) -
Improving low-performing schools through external assistance: Lessons from Chicago and California.
by: Kara S. Finnigan, et al.
Published: (2009) -
Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations
by: Ashley Jaksa, et al.
Published: (2023)